BioVaxys Technology EBIT

BioVaxys Technology (BVAXF) currently reports a EBIT of $-4.9M as of July 2025. That compares with $-5.9M in the prior-year period — up 17.8% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore BioVaxys Technology's EBIT history and peer comparisons.

BioVaxys Technology's EBIT increased from $-5.9M to $-4.9M — a 17.8% year-over-year increase (period ending July 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioVaxys Technology's EBIT of $-4.9M is lower than the Healthcare sector average of $99B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

BioVaxys Technology reported $-4.9M in EBIT as of July 2025. That compares with $-5.9M in the prior-year period — up 17.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-4.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for BioVaxys Technology, and consider following BVAXF for alerts when major investors trade the stock.